These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32907280)

  • 1. [Safety evaluation of mass inoculation of 23 valent pneumococcal polysaccharide vaccine among elderly people aged 60 and above in Shanghai from 2013 to 2017].
    Guo X; Qiu J; Ren J; Liu JC; Sun XD
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):929-933. PubMed ID: 32907280
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacy evaluation after 5 years of inoculation of 23 valent pneumococcal polysaccharide vaccine for the elderly aged 60 years old and above in Shanghai during 2013-2018].
    Guo X; Qiu J; Ren J; Ma XY; Huang ZY; Sun XD
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):923-928. PubMed ID: 32907279
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups.
    Liu Y; Xu Y; Wang J; Che X; Gu W; Du J; Zhang X; Zhang X; Jiang W; Chen J; An Z
    Hum Vaccin Immunother; 2021 Jan; 17(1):157-161. PubMed ID: 32530728
    [No Abstract]   [Full Text] [Related]  

  • 4. [Analysis on the project personnel's attitude and its influential factors of 23-valent pneumococcal polysaccharide vaccination program for the elderly in Shanghai].
    Guo X; Xu XX; Qiu J; Ren J; Sun XD
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):934-941. PubMed ID: 32907281
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Pneumococcal Diseases Among the Elderly Aged 60 Years or Older: A Matched Test Negative Case-Control Study in Shanghai, China.
    Sun X; Guo X; Qiu J; Zhao G; Xu X; Wagner AL; Jiang H; Huang Z; Ren J; Ma X; Liang X; Yao Y; Wu J; Lu Y
    Front Public Health; 2021; 9():620531. PubMed ID: 34616702
    [No Abstract]   [Full Text] [Related]  

  • 6. [The surveillance analysis of the adverse events following immunization of the domestic 13-valent pneumococcal polysaccharide conjugate vaccine in Zhejiang Province].
    Hu Y; Huang Z; Wang Y; Liang H; Pan XJ; Chen YP; Yuan L; Yang SY; Chen JJ; Chen YY; Yan XM; Tao Q; Qin X; Lyu HK
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Nov; 56(11):1625-1629. PubMed ID: 36372754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
    Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
    Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
    Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
    Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety of delayed vaccination with the national immunization program vaccines in children aged 0-6 years from 2019 to 2021 in Xuhui District, Shanghai City in China].
    Wu QS; Mao SQ; Xu Y; Gong RJ; Zhou Q; Liu M; Liu JY; Zhu DH; Guo X
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jul; 57(7):983-991. PubMed ID: 37482734
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
    Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
    Jiang Y; Gauthier A; Keeping S; Carroll S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy.
    Lu CL; Chang SY; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Hung CC
    Vaccine; 2014 Feb; 32(9):1031-5. PubMed ID: 24440112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annual report: Surveillance of adverse events following immunisation in Australia, 2011.
    Mahajan D; Cook J; Dey A; Macartney K; Menzies RI
    Commun Dis Intell Q Rep; 2012 Dec; 36(4):E315-32. PubMed ID: 23330706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance and compensation claims for adverse events following immunization from 2011 to 2016 in the Republic of Korea.
    Kim MK; Lee YK; Kim TE; Kong I; Yang HJ; Suh ES
    Clin Exp Vaccine Res; 2017 Jul; 6(2):146-155. PubMed ID: 28775979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly.
    Huang L; Wang L; Li H; Hu Y; Ru W; Han W; Shi G; Ye Q; Han Z; Xia J; Xia S; Xu M; Li J
    Hum Vaccin Immunother; 2019; 15(1):249-255. PubMed ID: 30215583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in 2 to 70 year old healthy people in China: A phase III double blind, randomized clinical trial.
    Li G; Liang Q; Shi J; Hu Y; Li H; Wei W; Zhu F; Ye Q
    Hum Vaccin Immunother; 2015; 11(3):699-703. PubMed ID: 25714798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
    Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
    Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.
    Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
    Clin Infect Dis; 2014 Feb; 58(4):517-25. PubMed ID: 24300040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of safety of haemophilus influenza type b(Hib) conjugate vaccine in postmarketing based on the immunization information management system].
    Wang Z; Ma F; Zhang J; Yu J; Kang G; Gao J
    Zhonghua Yu Fang Yi Xue Za Zhi; 2015 Jun; 49(6):475-80. PubMed ID: 26310329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.
    Andrews NJ; Waight PA; George RC; Slack MP; Miller E
    Vaccine; 2012 Nov; 30(48):6802-8. PubMed ID: 23000122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.